

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**SCHEDULE 14A**  
**Proxy Statement Pursuant to Section 14(a)**  
**of the Securities Exchange Act of 1934**  
**(Amendment No.    )**

---

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material under §240.14a-12

**Verve Therapeutics, Inc.**  
(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

- No fee required.
- Fee paid previously with preliminary materials.
- Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11.
- 
-



P.O. BOX 8016, CARY, NC 27512-0903

## Verve Therapeutics, Inc. Important Notice Regarding the Availability of Proxy Materials

**Stockholders Meeting to be held on  
June 15, 2023**

**For Stockholders of record as of April 20, 2023**

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

To view the proxy statement, annual report, directions to register for the annual meeting and voting instructions, go to:  
[www.proxydocs.com/VERV](http://www.proxydocs.com/VERV)

To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.



**For a convenient way to view proxy materials and VOTE go to  
[www.proxydocs.com/VERV](http://www.proxydocs.com/VERV)**



**Have the 12 digit control number located in the shaded box above available  
when you access the website and follow the instructions.**

*If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year's meeting, you must make this request on or before June 05, 2023.*

**To order paper materials, use one of the following methods.**

  
**INTERNET**  
[www.investorelections.com/VERV](http://www.investorelections.com/VERV)

  
**TELEPHONE**  
**(866) 648-8133**

  
**\* E-MAIL**  
[paper@investorelections.com](mailto:paper@investorelections.com)

When requesting via the Internet or telephone you will need the 12 digit control number located in the shaded box above.

\* If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located above) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

### Verve Therapeutics, Inc.

**Meeting Materials:** Notice of Meeting and Proxy Statement & Annual Report or Form 10-K

**Meeting Type:** Annual Meeting of Stockholders

**Date:** Thursday, June 15, 2023

**Time:** 10:00 AM, Eastern Time

**Place:** Annual Meeting to be held live via the Internet  
please visit [www.proxydocs.com/VERV](http://www.proxydocs.com/VERV) for more details

**You must register to attend the meeting online and/or participate at [www.proxydocs.com/VERV](http://www.proxydocs.com/VERV)**

**SEE REVERSE FOR FULL AGENDA**

# Verve Therapeutics, Inc.

## Annual Meeting of Stockholders

THE BOARD OF DIRECTORS RECOMMENDS A VOTE  
FOR ON EACH OF THE NOMINEES IN PROPOSAL 1 AND FOR PROPOSAL 2.

### PROPOSAL

1. Election of three Class II directors to our board of directors, each to serve until the 2026 annual meeting of stockholders;
  - 1.01 Alexander Cumbo
  - 1.02 Michael MacLean
  - 1.03 Sheila Mikhail, J.D.
  
2. Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.

Note: To consider and act upon other such business as may properly come before the meeting or any adjournment thereof.